X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
PRIMCYV® is a targeted therapy containing the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line treatment of adult patients with HR+, HER2- metastatic breast cancer.
Lead Product(s): Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: Primcyv
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2023
Details:
Dr. Reddy’s Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe is available in a carton containing two 5 mL single-dose prefilled syringes.
Lead Product(s): Fulvestrant
Therapeutic Area: Oncology Product Name: Fulvestrant-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2020
Details:
Truqap (capivasertib) is a first-in-class, potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3), is approved in combination with Faslodex (fulvestrant) for the treatment of advanced HER2-/HR+ breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Truqap (capivasertib) is a first-in-class, potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3), is approved in combination with Faslodex (fulvestrant) for the treatment of advanced HR-positive breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
The net proceeds will be used to advance Avenzo’s ARTS-021 (AVZO-021), a potentially best-in-class CDK2 selective inhibitor being studied in an ongoing U.S.-based Phase 1 clinical study for the treatment of HR+/HER2- metastatic breast cancer and other advanced solid tumors.
Lead Product(s): AVZO-021,Fulvestrant,Letrozole
Therapeutic Area: Oncology Product Name: ARTS-021
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: New Enterprise Associates
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 26, 2024
Details:
Relay Therapeutics expects to use net proceeds to advance RLY-2608, , a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia, towards registrational trial.
Lead Product(s): RLY-2608,Fulvestrant,Palbociclib
Therapeutic Area: Oncology Product Name: RLY-2608
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nextech
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 08, 2024
Details:
Under the agreement, Avenzo will develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally, excluding Greater China.
Lead Product(s): AVZO-021,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: ARTS-021
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avenzo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 04, 2024
Details:
Samuraciclib (CT7001) - an oral CDK7 inhibitor in combination with Fulvestrant is being evaluated in phase 2 clinical trials for the treatment of HER2- advanced breast cancer.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
GDC-0077 (inavolisib) is an investigational, highly selective inhibitor and degrader of mutant PI3K alpha. It is being evaluated in combination with palbociclib & fulvestrant for the treatment of HER2-negative breast cancer With a PIK3CA Mutation.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: GDC-0077
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Details:
eFT226 (zotatifin), a small molecule inhibitor of the RNA helicase eIF4A, is currently undergoing evaluation in Phase II clinical trials in combination with Fulvestrant for treating ER+ & HER2-negative Breast cancer.
Lead Product(s): Zotatifin,Fulvestrant
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Details:
GDC-0077 (inavolisib) is an oral therapy with high in vitro potency and selectivity for PI3Kα inhibition. It is being evaluated in phase 3 trials for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: GDC-0077
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
GDC-0077 (inavolisib palbociclib fulvestrant) is a PI3K alpha Inhibitor Small molecule drug candidate, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer with a PIK3CA mutation via oral tablet.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: GDC-0077
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
eFT226 (zotatifin) is a potent and sequence-selective small molecule inhibitor of the RNA helicase eIF4A. It is being evaluated in combination with fulvestrant and abemaciclib for treatment of ER+/HER2- advanced metastatic breast cancer.
Lead Product(s): Zotatifin,Fulvestrant,Abemaciclib
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
Truqap, a first-in-class AKT inhibitor, discovered by AstraZeneca subsequent to its collaboration with Astex, recently approved by FDA in combination with Faslodex, for treatment for adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $275.0 million Upfront Cash: $5.0 million
Deal Type: Collaboration November 22, 2023
Details:
Truqap (capivasertib), a first in class, oral targeted inhibitor of the cancer-driving protein AKT, was discovered by AstraZeneca subsequent to its discovery collaboration with Astex.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $275.0 million Upfront Cash: $5.0 million
Deal Type: Collaboration November 20, 2023
Details:
Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Details:
EA-114 (fulvestrant) is an estrogen receptor antagonist, which being developed for hormone-receptor-positive (HR+) metastatic breast cancer and company plans to file a new drug application for EA-114 in 2024
Lead Product(s): Fulvestrant
Therapeutic Area: Oncology Product Name: EA-114
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
The collaboration aims to evaluate the novel combination of CT7001 (samuraciclib), an oral, first-in-class inhibitor of CDK7, and Arvinas’ ARV-471 (vepdegestrant), an investigational oral PROTAC® estrogen receptor protein degrader being developed in metastatic breast cancer.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arvinas
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 06, 2023
Details:
AZD5363 (capivasertib) is an investigational orally and potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3) and in combination with Faslodex granted Priority Review in the US for patients with advanced HR-positive breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: AZD5363
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
STX-478 is a mutant-selective PI3Kα inhibitor with a potentially best-in-class profile, for the treatment of HR+/HER2- breast cancer and other solid tumors.'
Lead Product(s): STX-478,Fulvestrant
Therapeutic Area: Oncology Product Name: STX-478
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
RLY-2608 is a selective inhibitors of PI3K alpha. PI3K alpha is the most frequently mutated in all cancers, with oncogenic mutations detected in about 13% of patients with solid tumors. RLY-2608 is currently being evaluated for advanced solid tumors with a PIK3CA mutation.
Lead Product(s): RLY-2608,Fulvestrant
Therapeutic Area: Oncology Product Name: RLY-2608
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
The collaboration will aims to evaluate eFT226 (zotatifin) in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a pre-operative setting.
Lead Product(s): Zotatifin,Fulvestrant
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Stanford Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 11, 2023
Details:
BLU-222 is currently being evaluated in the Phase 1 dose escalation portion of the VELA trial. Patients have been treated with BLU-222 at doses ranging from 50 mg BID to 800 mg BID to date, with evidence of clinical benefit observed and no discontinuations due to AEs.
Lead Product(s): BLU-222,Fulvestrant
Therapeutic Area: Oncology Product Name: BLU-222
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
RLY-2608 is a selective inhibitors of PI3K alpha. PI3K alpha is the most frequently mutated in all cancers, with oncogenic mutations detected in about 13% of patients with solid tumors. RLY-2608 is currently being evaluated for advanced solid tumors with a PIK3CA mutation.
Lead Product(s): RLY-2608,Fulvestrant
Therapeutic Area: Oncology Product Name: RLY-2608
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
BLU-222 is currently being evaluated in the Phase 1 dose escalation portion of the VELA trial. Patients have been treated with BLU-222 at doses ranging from 50 mg BID to 800 mg BID to date, with evidence of clinical benefit observed and no discontinuations due to AEs.
Lead Product(s): BLU-222,Fulvestrant
Therapeutic Area: Oncology Product Name: BLU-222
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
Nerlynx (neratinib) is a kinase inhibitor that irreversibly binds to EGFR, HER2, and HER4. It reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathways, and showed antitumor activity in EGFR and/or HER2 expressing carcinoma cell lines.
Lead Product(s): Neratinib,Fulvestrant,Trastuzumab
Therapeutic Area: Oncology Product Name: Nerlynx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps1), for the treatment of adult patients with ER+/HER2- advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy.
Lead Product(s): CFI-402257,Fulvestrant
Therapeutic Area: Oncology Product Name: CFI-402257
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
eFT226 (Zotatifin) is a potent and sequence-selective small molecule inhibitor of eIF4A that is designed to suppress expression of a network of cancer driving proteins, including Cyclins D and E, CDKs 2, 4 and 6 and select RTKs as well as KRAS.
Lead Product(s): Zotatifin,Fulvestrant
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
The approved ANDA is equivalent to Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals. Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of breast cancer. Refer to our label for full indication.
Lead Product(s): Fulvestrant
Therapeutic Area: Oncology Product Name: Fulvestrant-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2022
Details:
PKI-587 (Gedatolisib) is a potent, reversible dual inhibitor that selectively targets all Class I PI3K isoforms and mTOR. Its in Phase 1b clinical trial in combination with palbociclib and endocrine therapy for patients with HR+/HER2- advanced breast cancer.
Lead Product(s): Gedatolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: PKI-587
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2022
Details:
Capivasertib (AZD 5363), is an investigational oral treatment currently in Phase III trials for the treatment of multiple subtypes of breast cancer, prostate cancer and a Phase II trial for haematologic malignancies.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: AZD 5363
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor (PR) that is orally administered. Currently, there are no approved therapies that selectively target PR+ cancers.
Lead Product(s): Onapristone,Fulvestrant
Therapeutic Area: Oncology Product Name: ONA-XR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
XL102 is a potent, selective and orally bioavailable small molecule CDK7 inhibitor, which is an important regulator of the cellular transcriptional and cell cycle machinery.
Lead Product(s): XL102,Fulvestrant
Therapeutic Area: Oncology Product Name: XL102
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Gedatolisib for the treatment of HR+/HER2- advanced breast cancer that has progressed after treatment with a CDK4/6 inhibitor in combination with an aromatase inhibitor.
Lead Product(s): Gedatolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: PKI-587
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
The Company intends to use the proceeds to fund ongoing and planned CT7001 (samuraciclib) clinical trials, ongoing development of its CDK12/13 inhibitor / Cyclin-K glue-degrader, and for working capital and general corporate purposes.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing December 01, 2022
Details:
CT7001 (samuraciclib), an oral CDK7 inhibitor, is a promising therapeutic strategy in cancer, as CDK7 regulates transcription of cancer-causing genes and promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 01, 2022
Details:
Under the terms of the agreement, Pfizer will provide global development capabilities and expertise to support Carrick’s Phase 2 study of CT-7001 (samuraciclib) in combination with fulvestrant for CDK4/6i-resistant HR+, HER2- advanced breast cancer.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 01, 2022
Details:
ZW49 (zanidatamab) is bispecific antibody, based on Zymeworks’ Azymetric™ platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding.
Lead Product(s): Zanidatamab,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: ZW49
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor (PR) that is orally administered. Preclinical and clinical data suggest that ONA-XR has anticancer activity by inhibiting progesterone receptor binding to chromatin.
Lead Product(s): Onapristone,Fulvestrant
Therapeutic Area: Oncology Product Name: ONA-XR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
NERLYNX® (neratinib) tablets, for oral use, is a kinase inhibitor indicated as a single agent, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
Lead Product(s): Neratinib,Fulvestrant,Trastuzumab
Therapeutic Area: Oncology Product Name: Nerlynx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
AZD 5363 (capivasertib) is an investigational oral treatment currently in Phase III trials for the treatment of multiple subtypes of breast cancer, prostate cancer and a Phase II trial for haematologic malignancies.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: AZD 5363
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Astex Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
SY-5609, a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, is currently being evaluated in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer.
Lead Product(s): SY-5609,Fulvestrant
Therapeutic Area: Oncology Product Name: SY-5609
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Kisqali (ribociclib) is a unique CDK4/6 inhibitor, consistently demonstrating statistically significant OS benefit while maintaining or improving quality of life across three Phase III trials, regardless of patient or disease characteristics.
Lead Product(s): Ribociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: Kisqali
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Translational Research In Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali® (ribociclib).
Lead Product(s): Ribociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: Kisqali
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
The results suggest that the combination of Nerlynx (neratinib), fulvestrant, and trastuzumab together is promising for treating HR+ and HER2-mutated MBC with prior exposure to CDK4/6i across a range of HER2 mutations.
Lead Product(s): Neratinib,Fulvestrant,Trastuzumab
Therapeutic Area: Oncology Product Name: Nerlynx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Efficacy results from the BTC cohort of 25 patients for Nerlynx (Neratinib) demonstrated an overall response rate (ORR) of 16%, 95% CI 4.5-36.1%), median progression free survival (PFS) of 2.8 months and overall survival (OS) of 5.4 months.
Lead Product(s): Neratinib,Fulvestrant,Trastuzumab
Therapeutic Area: Oncology Product Name: Nerlynx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
In new exploratory analysis of data from MONALEESA-2 study, Kisqali (ribociclib) plus letrozole maintained an OS benefit for postmenopausal patients with metastatic breast cancer treated in first-line, including for those patients who required dose modification of Kisqali.
Lead Product(s): Ribociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: Kisqali
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Astex Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
NERLYNX (Neratinib) is prescription medicine used alone to treat adults with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer and who have previously been treated with trastuzumab-based therapy.
Lead Product(s): Neratinib,Fulvestrant,Trastuzumab
Therapeutic Area: Oncology Product Name: Nerlynx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
With further follow-up of MONALEESA-3, Kisqali (ribociclib) plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for postmenopausal women living with HR+/HER2- aBC.
Lead Product(s): Ribociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: Kisqali
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Astex Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
